ESHAP Regimen

Ultima Vez Modificado: 7 de diciembre del 2008

Share article


Imprima English

Question

Dear OncoLink "Ask The Experts,"

My question is about the ESHAP protocol for lymphoma. The most descriptive protocol I've been able to find states to run cisplatin for 4 days with concurrent doses of etoposide during that time. I have oncology coworkers who are questioning the safety of running 2 chemo drugs concurrently, and would rather stop the cisplatin, run the etoposide, then continue the cisplatin. I'm thinking that perhaps there is a synergistic action between these 2 drugs and a reason to run them together?

Answer

Michael Vozniak, PharmD, BCOP, Hematology/Oncology Clinical Pharmacy Specialist, responds:

ESHAP stands for etoposide, methylprednisolone, high-dose cytarabine, and cisplatin.

Etoposide (VP-16) is known to have synergistic activity when given with cisplatin, but the effect is likely the same whether or not they are given concurrently or back-to-back.

An important part of the ESHAP regimen is the cisplatin that is given by continuous infusion for (hopefully) maximal cell death. Early studies gave cisplatin over 24 hours, but toxicity was high, so we now give it over several days in order to reduce toxicity. Physicians would rather that the continuous infusion NOT be interrupted, and there really is no reason to do so. The two medications are compatible in the IV and there are no safety concerns with running these drugs together. Below is the protocol we use at our institution and a reference that discusses the protocol’s results in trials.

Treatment Plan:

  • Etoposide 40mg/m2/day IV Day 1, 2, 3 and 4
  • Solumedrol 500mg/day IV Day 1, 2, 3, 4 and 5
  • Cytarabine 2Gm/m2/day IV Day 5 -To start immediately after Cisplatin completed.
  • Cisplatin 25mg/m2/day IV Day 1, 2, 3 and 4; Given as a continuous infusion over 24 hours.

Special Instructions:

  • Regimen (Cisplatin, and Cytarbine) is emetogenic and should never be given without antiemetic pre-medication (Level 5).
  • Aggressive hydration with Cisplatin.
  • Urinary output >100cc's/hour prior to Cisplatin and for duration of therapy.
  • Decadron eye drops with Cytarabine.
  • Cerebellar function checks prior to each Cytarabine dose.
  • VP16-vital signs per nursing protocol.

Velasquez, WS et al. (1994) ESHAP – An Effective Chemotherapy Regimen in Refractory and Relapsing Lymphoma: A 4 Year Follow Up Study. Journal of Clinical Oncology, 12(6): 1169-1176.

Imprima English
News
Studies outline new options for the standard treatment of various lymphoma types

Dec 7, 2010 - Rituximab may be a better option than watchful waiting in some lymphoma patients, and a new treatment option appears effective for relapsed or refractory Hodgkin's lymphoma, according to two studies being presented at the annual meeting of the American Society of Hematology, held from Dec. 4 to 7 in Orlando, Fla. Other research being presented will highlight new options for the standard treatment of advanced asymptomatic follicular lymphoma; mantle cell lymphoma; and early, unfavorable Hodgkin's disease.



I Wish You Knew

Understanding prostate cancer screening

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información